Theratechnologies - President and CEO, Paul Lévesque.
President and CEO, Paul Lévesque.
Source: Theratechnologies.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Theratechnologies (TH) and partners contributed $2 million for a collective research project for a new treatment for metastatic cancer
  • TH1902 is the proposed drug for cancer therapy but is still in development
  • The drug helps deliver a chemotherapeutic agent directly into cancer cells
  • The project will evaluate the potential of the compound in metastatic cancer models
  • Theratechnologies (TH) is up 1.14 per cent trading at $2.65 per share as of 4:07 p.m. ET

Theratechnologies (TH), CQDM, and the Quebec Breast Cancer Foundation have contributed $2 million in funding for a collective research project studying a new treatment for metastatic cancer.

The company stated this project will occur at the Université du Québec à Montréal (UQAM) and builds directly on a previous CQDM-funded study also involving the university’s and Theratechnologies’ teams.

TH1902 is the proposed new therapeutic approach against cancer but is still in development.

Theratechnologies describes TH1902 as helping deliver a chemotherapeutic agent directly into cancer cells through the recognition and internalizing function of a protein called sortilin, which is overexpressed on the surface of the cells.

The collaborative project will evaluate the potential of the compound in several metastatic cancer models. The company stated that if the hypothesis is confirmed, the project will increase the spectrum of cancer patients who may benefit from this new therapy.

“The enormous potential of TH1902 to treat several types of cancer motivates us to accelerate its development… This collaboration will allow us to increase its potential to change the lives of those touched by such a devastating disease,” Paul Lévesque, President and CEO of Theratechnologies, said.

Theratechnologies (TH) is up 1.14 per cent trading at $2.65 per share as of 4:07 p.m. ET.

More From The Market Herald

" Update from Revive Therapeutics (CSE:RVV) on Phase 3 clinical trial for Bucillamine in COVID-19

Revive Therapeutics (RVV) has provided an update on the company’s U.S. Food & Drug Administration (FDA) Phase 3 clinical trial.

" Core One Labs (CSE:COOL) subsidiary Vocan successfully converts Psilocin precursor into Psilocybin

Core One Labs (CSE:COOL) subsidiary Vocan Biotechnologies has converted psilocin developed by Awakened Biosciences into viable API psilocybin.

" Small Pharma (TSXV:DMT) receives approval for DMT-assisted psychotherapy & SSRI drug study

Small Pharma (DMT) has received approval to initiate a drug interaction clinical trial in the U.K.

" Kovo HealthTech (TSXV:KOVO) sees 211 per cent year-over-year revenue growth

Kovo HealthTech Corp. (KOVO) reported its Q2 financial results for the period ending June 30, 2022.